| Objective:Observation of plasma N-terminal B-type natriuretic peptide (NT-proBNP) concentration variation in patients with heart failure, to evaluate its clinical value in disease evaluation, prognosis and efficacy.Methods:From January2011to January2013heart failure patients hospitalized for study in Cardiovascular Medicine in Fenyang Hospital of Shanxi, for148patients with chronic heart failure and98patients with acute left heart failure, plasma NT-proBNP concentration is detected within24hours after admission. Every three months follow-up1, follow-up period is one year. Based on follow-up outcomes, it were divided into study group and control group. The study group with cardiac events include heart failure readmissions or cardiac death; cardiac events did not occur in the control group. Each group plasma NT-proBNP concentrations were compared. From June2012to January2013, for59patients with heart failure, the plasma NT-proBNP concentration is detected within24hours after admission and7days after the formal anti-heart failure treatment and compared. The results given are the χ±s. T test was used to compare between groups. SPSS13.0was used for statistical analyses.Results:1Study group patients with cardiac events, its plasma NT-proBNP concentration was4666±304.6pg/ml; control group without cardiac events, its plasma NT-proBNP concentration was2033±162.3pg/ml. The plasma NT-proBNP concentration in study group was higher than in control group, the difference was statistically significant (P<0.0001). So the plasma concentration of NT-proBNP has a predictive value for the prognosis of patients with chronic heart failure. 2Study group patients with acute left ventricular failure, plasma NT-proBNP concentration was2640±255.2pg/ml, the concentration was1696±124.2pg/ml in control group. The study group was higher and the difference had statistically significant (P=0.0093), illustrated the plasma concentration of NT-proBNP have predictive value for prognosis of patients with acute left ventricular failure.3For HF readmission in study group, plasma NT-proBNP concentration was2179±159.4pg/ml and for cardiac death it was4595±100.4pg/ml. The difference was statistically significant (P<0.0001).4For heart failure patients, plasma NT-proBNP concentration was3727±526.4pg/ml within24hours after admission and was2241±343.2pg/ml after7days the formal anti-heart failure treatment. Pre-treatment plasma NT-proBNP concentrations decreased over the treatment and P value was0.0223with statistical significance, so the plasma levels of NT-proBNP can be used to evaluate the efficacy of heart failure patients.Conclusion:1Whether patients with chronic heart failure or acute left heart failure patients, study group plasma NT-proBNP concentrations were higher, indicating that NT-proBNP is a better objective indicators in the judgment of the severity of heart failure. The plasma concentration of NT-proBNP has a prognostic value so that the prognosis with higher plasma NT-proBNP is poor.2After treatment the plasma NT-proBNP concentration decreased, indicating plasma NT-proBNP levels can be used to evaluate the efficacy of heart failure patients. |
PDF Full Text Request